ArticleJournal for immunotherapy of cancer2021

Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.